Educational paper. Connective tissue disorders with vascular involvement: from gene to therapy
Related Experiment Video
Updated: May 20, 2026

Engineering Tendon Assembloids to Probe Cellular Crosstalk in Disease and Repair
Published on: March 22, 2024
Lut Van Laer1, Dorien Proost, Bart L Loeys
1Center for Medical Genetics, Faculty of Medicine and Health Sciences, University of Antwerp and Antwerp University Hospital, Prins Boudewijnlaan 43, 2650 Antwerp, Edegem, Belgium.
Insights
Heritable connective tissue diseases, including thoracic aortic aneurysm/dissection, involve extracellular matrix and transforming growth factor beta (TGFβ) signaling. New therapies targeting TGFβ signaling are in clinical trials.
Area of Science:
- Genetics and Molecular Biology
- Cardiovascular Medicine
- Rheumatology
Background:
- Heritable connective tissue diseases are multisystemic disorders with significant morbidity and mortality.
- These diseases involve extracellular matrix defects and altered cytokine sequestration, notably transforming growth factor beta (TGFβ).
Purpose of the Study:
- To review clinical characteristics, molecular findings, and therapeutic strategies for syndromic and non-syndromic thoracic aortic aneurysm/dissection.
- To highlight the role of disturbed TGFβ signaling in these conditions.
Main Methods:
- Review of existing literature on heritable connective tissue diseases.
- Analysis of clinical and molecular data related to thoracic aortic aneurysm/dissection.
- Examination of therapeutic strategies targeting TGFβ signaling.
Main Results:
- Disturbed TGFβ signaling is implicated in various heritable connective tissue diseases, including Marfan syndrome, Loeys-Dietz syndrome, and thoracic aortic aneurysm/dissection.
- These findings have identified new therapeutic targets.
Conclusions:
- Angiotensin II type 1 receptor antagonists, which inhibit TGFβ signaling, are under investigation in large clinical trials.
- Understanding the molecular basis of these diseases is crucial for developing effective treatments for thoracic aortic aneurysm/dissection.
Abstract:
Heritable connective tissue diseases comprise a heterogeneous group of multisystemic disorders that are characterized by significant morbidity and mortality. These disorders do not merely result from defects in the amount or structure of one of the components of the extracellular matrix, as the extracellular matrix also serves other functions, including sequestration of cytokines, such as transforming growth factor beta (TGFβ). Indeed, disturbed TGFβ signaling was demonstrated in several heritable connective tissue diseases, including syndromic forms such as Marfan or Loeys-Dietz syndrome and non-syndromic presentations of thoracic aortic aneurysm/dissection. Because of these findings, new therapeutic targets have been unveiled, leading to the initiation of large clinical trials with angiotensin II type 1 receptor antagonists that also have an inhibiting effect on TGFβ signaling. Here, we present an overview of the clinical characteristics, the molecular findings, and the therapeutic strategies for the currently known syndromic and non-syndromic forms of thoracic aortic aneurysm/dissection.
Related Concept Videos
Connective Tissue Cell Types
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Overview of the Vascular System
Introduction to Connective Tissues
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Inflammatory Response I: Vascular and Cellular
Functions of Connective Tissues
Hard connective tissues, such as bones and cartilage, provide structure and support to the body.

